Peregrine Pharmaceuticals Inc. (Nasdaq: PPHM) ended a Phase III SUNRISE trial of bavituximab in patients with previously treated locally advanced or metastatic non-squamous non-small cell lung cancer. The stock price plunged 66 cents to $0.40.
Peregrine Pharmaceuticals ends trial
February 26, 2016 at 12:16 PM EST
